Comparative Pharmacology
Head-to-head clinical analysis: KEMADRIN versus TRIHEXYPHENIDYL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEMADRIN versus TRIHEXYPHENIDYL HYDROCHLORIDE.
KEMADRIN vs TRIHEXYPHENIDYL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting anticholinergic agent that blocks muscarinic receptors in the basal ganglia, reducing cholinergic overactivity and restoring dopamine-acetylcholine balance.
Trihexyphenidyl is an anticholinergic agent that competitively blocks central muscarinic receptors (primarily M1) in the striatum, restoring the balance between acetylcholine and dopamine in the basal ganglia. It also has mild peripheral anticholinergic effects.
2.5 mg orally three times daily, increased gradually to 5 mg three to four times daily if necessary; maximum 15-20 mg daily.
1 mg orally initially, then increase by 2 mg every 3-5 days up to 6-10 mg daily in 3-4 divided doses; maximum 15 mg/day.
None Documented
None Documented
6-10 hours in adults (terminal elimination half-life); may be prolonged in elderly or renal impairment.
10-17 hours; clinical context: steady-state concentrations achieved in 2-3 days.
Primarily renal as unchanged drug and metabolites (approximately 50% unchanged); minor biliary/fecal elimination (<10%).
Renal (primarily as unchanged drug and metabolites; <15% unchanged) and biliary/fecal (minor).
Category C
Category C
Anticholinergic Antiparkinsonian
Anticholinergic Antiparkinsonian